PubMed Health⌕ Search

PubMed · 1122491

Lymphoma presenting as bone marrow failure.

Abstract

In reviewing 550 patients with non-Hodgkin's lymphoma, only 3 percent were found to present with severe leukopenia or thrombocytopenia due to bone marrow infiltration. Patients with well-differentiated lymphoma had a favorable prognosis despite the presence of cytopenia. In contrast, individuals with poorly differentiated lymphoma had a median survival of only 4 months. Thus, the critical factor in survival was the degree of differentiation of the lymphoma. Conventional therapy proved of little value in the poorly differentiated group. Trials of intensive multidrug chemotherapeutic regimens seem warranted, despite the risk of exacerbating the cytopenia.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Koziner, L Ellman, A C Aisenberg. 1975. Lymphoma presenting as bone marrow failure.. https://doi.org/10.1002/1097-0142(197505)35%3A5%3C1426%3A%3Aaid-cncr2820350528%3E3.0.co%3B2-a

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Long-lasting partial remission by Interferon-alpha treatment in a child with essential thrombocythemia.

Essential thrombocythemia (ET) is a clonal myeloproliferative disorder characterized by sustained thrombocytosis, isolated hyperplasia of megakaryocytic lineage, and association with thrombotic or bleeding episodes. It is extremely rare in childhood and frequently presents without evident clinical signs. We describe a 3-year-old girl with severe headache and dizziness suffering from ET, who was treated with Interferon-alpha-2a (IFN) based on the potent effect of this agent to inhibit myeloid colonies induced by phytohemagglutinin A stimulated leukocyte conditioned medium (PHA-LCM). Bone-marrow-derived mononuclear cells of this patient did not exhibit spontaneous colony formation but responded to recombinant human (rh) erythropoietin (EPO), rh granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF, and stem-cell factor in addition to PHA-LCM. After 65 months of in vivo IFN treatment, the patient experienced a sustained partial remission with platelet counts varying between 400 and 600 x 10(3)/microl.

Bone Marrow Examination↗